Age of women as a parameter Affecting CA-125, TSH and CBC
A Correlation Study
Abstract
One of the Cancer’s antigens is the CA125, which is a protein antigen, found at excessively high levels in females characterized with ovarian cancer. It is suggested for ovarian cancer screening of women that are at higher risk to get the disease, despite its limited sensitivity and specificity. This study is conducted to identify possible correlations between CA125 and TSH levels with parameters of hematological origin among women of different ages. This study included 44 healthy looking females. Most but not all patients were from Erbil. The study revealed that, CA125 and TSH levels were not associated. Also, the elevation of the CA125 levels in the females could be related to other non-cancerous factors such as menstrual cycle, or postmenopausal. Also WBC parameters and Hb levels were not affected by CA125. The only parameter that was affected by CA125 elevation was RBCs. The research recorded a significant difference of RBC between patient group and control group. Also recorded, no difference to be considered as an indication related to the difference in women age.
Downloads
References
Z. R. Yurkovetsky, F. Y. Linkov, D. E Malehorn and A. E. Lokshin. Multiple biomarker panels for early detection of ovarian cancer. Future Oncology, vol. 2, no. 6, pp. 733-741, 2006.
K. A. Sikaris. CA125-A test with a change of heart. Heart, Lung and Circulation, vol. 20, no. 10, pp. 634-640, 2011.
R. C. Bast, D. Badgwell, Z. Lu, R. Marquez, D. Rosen, J. Liu, K. A. Baggerly, E. N. Atkinson, S. Skates, Z. Zhang, A. Lokshin, U. Menon, I. Jacobs and K. Lu. New tumor markers: CA125 and beyond. International Journal of Gynecologic Cancer, vol. 15, pp. 274-281, 2005.
A. N. Minlikeeva, J. L. Freudenheim, R. A. Cannioto, K. H. Eng, J. B. Szender, P. Mayor, J. L Etter, D. W. Cramer, B. Diergaarde, J. A. Doherty, T. Dörk, R. Edwards, A. deFazio, G. Friel, M. T Goodman, P. Hillemanns, E. Høgdall, A. Jensen, S. J. Jordan, B. Y. Karlan, S. K. Kjær, R. Klapdor, K. Matsuo, M. Mizuno, C. M. Nagle, K. Odunsi, L. Paddock, M. A. Rossing, J. M. Schildkraut, B. Schmalfeldt, B. H. Segal, K. Starbuck, K. L. Terry, P. M. Webb, E. Zsiros, R. B. Ness, F. Modugno, E. V. Bandera, J. Chang-Claude and K. B. Moysich. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, vol. 117, no. 7, pp. 1063-1069, 2017.
E. Shinderman-Maman, K. Cohen, C. Weingarten, D. Nabriski, O. Twito, L. Baraf, A. Hercbergs, P. J. Davis, H. Werner, M. Ellis and O. Ashur-Fabian. The thyroid hormone-αvβ3 integrin axis in ovarian cancer: Regulation of gene transcription and MAPKdependent proliferation. Oncogene, vol. 35, no. 15, pp. 1977-1987, 2016.
R. Kimura, K. Imaeda, T. Mizuno, K. Wakami, K. Yamada, N. Okayama, Y. Kamiya and T. Joh. Severe ascites with hypothyroidism and elevated CA125 concentration: A case report. Endocrine Journal, vol. 54, no. 5, pp. 751-755, 2007.
K. A. Williams, S. I. Labidi-Galy, K. L. Terry, A. F. Vitonis, W. R. Welch, A. Goodman and D. W. Cramer. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecologic Oncology, vol. 132, no. 3, pp. 542-550, 2014.
M. U. Ceran, U. Tasdemir, E. Colak and T. Güngör. Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis?-a survival analysis. Journal of Ovarian Research, vol. 12, no. 1, p. 16, 2019.
A. G. Van Der Zee, H. W. De Bruijn, M. Krans, E. M. De Cuyper, H. Hollema, P. C. Limburg, H. W de Bruijn, H. Hollema, J. Bijzet, M. Krans and E. G. de Vries. Higher levels of interleukin‐6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts. Cancer, vol. 75, no. 4, pp. 1004-1009, 1995.
A. Maccio, C. Madeddu, D. Massa, M. C. Mudu, M. R. Lusso, G. Gramignano, R. Serpe, G. B. Melis and G. Mantovani. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. Blood, vol. 106, no. 1, pp. 362-367, 2005.
E. Lengyel. Ovarian cancer development and metastasis. The American Journal of Pathology, vol. 177, no. 3, pp. 1053-1064, 2010.
C. H. Holschneider and J. S. Berek. Ovarian cancer: Epidemiology, biology, and prognostic factors. In: Seminars in Surgical Oncology, Springer, Berlin, pp. 3-10, 2000.
F. Salehi, L. Dunfield, K. P. Phillips, D. Krewski and B. C. Vanderhyden. Risk factors for ovarian cancer: An overview with emphasis on hormonal factors. Journal of Toxicology and Environmental Health, Part B, vol. 11, pp. 301-321, 2008.
A. S. M. J. Homady M. H., M. H. Ubeid, M. Salih, T. S. and Al-Jubori, M. Age and gender in relation to colorectal cancer in najef province: A histopathological study. Acta Scientific Pharmaceutical Sciences, vol. 5, pp. 21-27, 2021.
W. K. Eo, K. H. Kim, E. J. Park, H. Y. Kim, H. B. Kim, S. B. Koh and J. Namkung. Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. Journal of Cancer, vol. 9, pp. 1165-1172, 2018.
Committee on the State of the Science in Ovarian Cancer Research; Board on Health Care Services; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Ovarian Cancers: Evolving Paradigms in Research and Care. National Academies Press, Washington, DC, 2016.
J. A. Rauh-Hain, T. C. Krivak, M. G. Del Carmen and A. B. Olawaiye. Ovarian cancer screening and early detection in the general population. Reviews in Obstetrics and Gynecology, vol. 4, no. 1, pp. 15-21, 2011.
M. Thun, M. S. Linet, J. R. Cerhan, C. A. Haiman and D. Schottenfeld. Cancer Epidemiology and Prevention: Oxford University Press, Oxford, 2017.
N. Mahdavifar, R. Pakzad, M. Ghoncheh, H. S. Gandomani and H. Salehiniya. Epidemiology, incidence, and mortality of gallbladder cancer and its relation with development in the world. Annals of Tropical Medicine and Public Health, vol. 10, pp. 563-517, 2017.
Y. Moradi, M. Jafari, S. Chaichian, S. Khateri, A. Akbarian, B. Moazzami, K. Mansori, Y. Mahmodi and S. Samie. Trends in ovarian cancer incidence in Iran. International Journal of Cancer Management, vol. 9, p. e5452, 2016.
N. Bhatla and A. Jones. The World Ovarian Cancer Coalition Atlas. Global Trends in Incidence, Mortality and Survival. The World Ovarian Cancer Coalition, Toronto, ON. 2018.
R. Bast, M. Feeney, H. Lazarus, L. M. Nadler, R. B. Colvin and R. C. Knapp. Reactivity of a monoclonal antibody with human ovarian carcinoma. The Journal of Clinical Investigation, vol. 68, no. 5, pp. 1331-1337, 1981.
N. Scholler and N. Urban. CA125 in ovarian cancer. Biomarkers in Medicine, vol. 1, no. 4, pp. 513-523, 2007.
H. Yesilyurt, B. Seckin, A. Aktulay and S. Ozyer. Age-stratified analysis of tumor markers and tumor characteristics in adolescents and young women with mature cystic teratoma. Journal of the Chinese Medical Association, vol. 81, pp. 499-504, 2018.
K. A. Habib, M. G. Jumaa and M. J. Hussein. Determination of serum CA125 and evaluate its efficiency as screening tool for early detection of ovarian tumors. Baghdad Science Journal, vol. 12, pp. 55-62, 2015.
M. H. Ubeid. Prevalence of leukocytes in Type 2 diabetic patients in Erbil City. Medical Journal of Babylon, vol. 17, p. 19, 2020.
C. L. Gyftaki, E. Politi, M. Liontos, K. Saltiki, N. Theocharis Papageorgiou, D. H. Thomakos, D. Haidopoulos, A. Rodolakis, M. Alevizaki, A. Bamias and A. Dimopoulos. Differential transcriptional and protein expression of thyroidstimulating hormone receptor in ovarian carcinomas. International Journal of Gynecological Cancer, vol. 24, no. 5, pp. 851-856, 2014.
M. Rae, O. Gubbay, A. Kostogiannou, D. Price, H. Critchley and S. Hillier. Thyroid hormone signaling in human ovarian surface epithelial cells. The Journal of Clinical Endocrinology and Metabolism, vol. 92, pp. 322-327, 2007.
M. Rasool, M. I. Naseer, K. Zaigham, A. Malik, N. Riaz, R. Alam, A. Manan, I. A. Sheikh, M. Asif. Comparative study of alterations in Tri-iodothyronine (T3) and Thyroxine (T4) hormone levels in breast and ovarian cancer. Pakistan Journal of Medical Sciences, vol. 30, p. 1356, 2014.
K. Żak, S. Niedobylski, M. Leziak, K. Maliszewska, M. Czapska and K. Skórzyńska-Dziduszko. Have thyroid hormones an impacton ovarian cancer? Journal of Education, Health and Sport, vol. 8, pp. 803-809, 2018.
M. Den Ouden, J. Ubachs, J. Stoot and J. Van Wersch. Whole blood cell counts and leucocyte differentials in patients with benign or malignant ovarian tumours. European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 72, pp. 73-77, 1997.
A. S. Juma, M. H. Ubeid and T. S. Salih. Anti-toxoplasma, anti-rubella, and anti-cytomegalovirus antibodies in dumpsite workers of Erbil Governorate. Cihan University-Erbil Scientific Journal, vol. 3, pp. 85-89, 2019.
A. S. Juma, M. H. Ubeid, S. S. Haydar and T. S. Salih. Some immunological and hematological parameters among refugees in kawergosk camp-erbil governorate. Cihan University-Erbil Scientific Journal, vol. 3, pp. 80-84, 2019.
R. S. Nomelini, T. M. da Silva, B. M. T. Murta and E. F. C. Murta. Parameters of blood count and tumor markers in patients with borderline ovarian tumors: A retrospective analysis and relation to staging. International Scholarly Research Notices, vol. 2012, p. 947831, 2012.
G. E. Krassas. Thyroid disease and female reproduction. Fertility and Sterility, vol. 74, pp. 1063-1070, 2000.
J. H. Kang, A. S. Kueck, R. Stevens, G. Curhan, I. De Vivo, B. Rosner, Erik Alexander, S. S. Tworoger. A large cohort study of hypothyroidism and hyperthyroidism in relation to gynecologic cancers. Obstetrics and Gynecology International, vol. 2013, p. 743721, 2013.
T. M. Markman, M. Markman and B. W. Clark. Case of ovarian cancer in a woman with undiagnosed graves’ disease: A case report and review of the literature. Case Reports in Oncology, vol. 10, pp. 452-454, 2017.
M. Bekmezci and O. Gunenc. The role of neutrophil/lymphocyte ratio (NLR) with ca 125 in preoperative predictıon of malignancy in adnexial mass. Medicine, vol. 7, pp. 857-60, 2018.
S. Bishara, M. Griffin, A. Cargill, A. Bali, M. Gore, S. Kaye, J. H. Shepherd, P. O. Van Trappen. Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 138, pp. 71-75, 2008.
M. Yildirim, B. D. Cendek and A. F. Avsar. Differentiation between benign and malignant ovarian masses in the preoperative period using neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios. Molecular and Clinical Oncology, vol. 3, pp. 317-321, 2015.
T. S. Salih, A. S. Juma and M. H. Ubeid. Occupational exposures and associated health effects among dumpsite workers. Cihan University-Erbil Scientific Journal, vol. 5, pp. 1-5, 2021.
Y. Qin, P. Wang, Z. Huang, G. Huang, J. Tang, Y. Guo, P. Huang, Z. Lai and F. Lin. The value of red cell distribution width in patients with ovarian cancer. Medicine, vol. 96, p. e6752, 2017.
A. Obermair, A. Handisurya, A. Kaider, P. Sevelda, H. Kölbl and G. Gitsch. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinoma patients: A prospective review. Cancer, vol. 83, pp. 726-731, 1998.
Z. Förhécz, T. Gombos, G. Borgulya, Z. Pozsonyi, Z. Prohászka and L. Jánoskuti. Red cell distribution width in heart failure: Prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. American Heart Journal, vol. 158, pp. 659-666, 2009.
P. Lehtovirta, D. Apter and U. H. Stenman. Serum CA 125 levels during the menstrual cycle. British Journal of Obstetrics and Gynaecology, vol. 97, pp. 930-933, 1990.
A. S. Juma and M. H. Ubeid. A Microbiological survey of ear infections in inhabitants of Erbil City. Cihan University-Erbil Scientific Journal, vol. 6, pp. 62-67, 2022.
C. C. Johnson, B. Kessel, T. L. Riley, L. R. Ragard, C. R. Williams, J. L. Xu, S. S. Buys and Prostate, Lung, Colorectal and Ovarian Cancer Project Team. The epidemiology of CA-125 in women without evidence of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. Gynecologic Oncology, vol. 110, pp. 383-389, 2008.
N. S. Joo, K. N. Kim and K. S. Kim. Serum CA125 concentration has inverse correlation with metabolic syndrome. Journal of Korean Medical Science, vol. 26, pp. 1328-1332, 2011.
N. T. Kouris, I. D. Zacharos, D. D. Kontogianni, G. S. Goranitou, M. D. Sifaki, H. E. Grassos, E. M. Kalkandi and D. K. Babalis. The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. European Journal of Heart Failure, vol. 7, pp. 199-203, 2005.
H. M. Turk, H. Pekdemir, S. Buyukberber, A. Sevinc, C. Camci, R. Kocabas, Tarakcioglu and N. M. Buyukberbe. Serum CA 125 levels in patients with chronic heart failure and accompanying pleural fluid. Tumor Biology, vol. 24, pp. 172-175, 2003.
Copyright (c) 2023 Muhsin H. Ubeid, Ameena S. M. Juma, Tanya S. Salih, Shilan S. Kamel, Shakir M. Al-Awqati
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-ND 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
